EcoDrugPlus

Proteasome 20s Subunit Alpha 6a

Ensembl ID : ENSSMAG00000011389
Gene Symbol: PSMA6A
1 Cross references
244 Possible Orthologues:

Proteasome 20s Subunit Alpha 8

Ensembl ID : ENSSMAG00000020374
Gene Symbol: PSMA8
3 Cross references
182 Possible Orthologues:

Proteasome 20s Subunit Beta 1

Ensembl ID : ENSSMAG00000004846
Gene Symbol: PSMB1
2 Cross references
217 Possible Orthologues:

Proteasome 20s Subunit Beta 5

Ensembl ID : ENSSMAG00000014870
Gene Symbol: PSMB5
1 Cross references
203 Possible Orthologues:

Proteasome 20s Subunit Beta 6

Ensembl ID : ENSSMAG00000004994
Gene Symbol: PSMB6
1 Cross references
230 Possible Orthologues:

Proteasome 20s Subunit Beta 7

Ensembl ID : ENSSMAG00000008020
Gene Symbol: PSMB7
3 Cross references
216 Possible Orthologues:

Proteasome 20s Subunit Beta 8a

Ensembl ID : ENSSMAG00000017264
Gene Symbol: PSMB8A
3 Cross references
218 Possible Orthologues:

Proteasome 20s Subunit Beta 9a

Ensembl ID : ENSSMAG00000016444
Gene Symbol: PSMB9A
3 Cross references
208 Possible Orthologues:

Proteasome 26s Subunit Ubiquitin Receptor, Non-Atpase 4b

Ensembl ID : ENSSMAG00000017291
Gene Symbol: PSMD4B
1 Cross references
220 Possible Orthologues:

Proteasome 26s Subunit, Atpase 1b

Ensembl ID : ENSSMAG00000004312
Gene Symbol: PSMC1B
3 Cross references
285 Possible Orthologues:

Proteasome 26s Subunit, Atpase 2

Ensembl ID : ENSSMAG00000001057
Gene Symbol: PSMC2
3 Cross references
232 Possible Orthologues:

Proteasome 26s Subunit, Atpase 4

Ensembl ID : ENSSMAG00000004534
Gene Symbol: PSMC4
3 Cross references
197 Possible Orthologues:


PREMIER has received funding from the Innovative Medicines Initiative 2 Joint Undertaking (JU) under grant agreement No 875508. The JU receives support from the EU’s Horizon 2020 research and innovation programme and the European Federation of Pharmaceutical Industries and Associations (EFPIA). The views reflect only the authors’ perspective and the JU is not responsible for any use that may be made of the information this manuscript contains. Elements of the website have been developed under projects PREMIER and the Biocenter Finland Drug Discovery and Chemical Biology network. CSC-IT is thanked for providing computational resources. Content of the website is provided without guarantee for correctness. Data has been collected and integrated from multiple public sources, for the largest: FDA, HUGO Gene Nomenclature Committee, ChEMBL, IUPHAR/BPS guide to pharmacology, Reactome, UniProt, and Ensembl. Credit is given to Ensembl for collecting species images (provided under public domain licences such as Wikimedia and NHGRI).

PREMIER has received funding from the Innovative Medicines Initiative 2 Joint Undertaking (JU) under grant agreement No 875508. The JU receives support from the EU’s Horizon 2020 research and innovation programme and the European Federation of Pharmaceutical Industries and Associations (EFPIA). The views reflect only the authors’ perspective and the JU is not responsible for any use that may be made of the information this manuscript contains.

Elements of the website have been developed under projects PREMIER and the Biocenter Finland Drug Discovery and Chemical Biology network. CSC-IT is thanked for providing computational resources. Content of the website is provided without guarantee for correctness. Data has been collected and integrated from multiple public sources, for the largest: FDA, HUGO Gene Nomenclature Committee, ChEMBL, IUPHAR/BPS guide to pharmacology, Reactome, UniProt, and Ensembl. Credit is given to Ensembl for collecting species images (provided under public domain licences such as Wikimedia and NHGRI).